Intra- and extra-hospital improvement in ischemic stroke patients: influence of reperfusion therapy and molecular mechanisms.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
26 02 2020
Historique:
received: 29 11 2018
accepted: 31 01 2020
entrez: 28 2 2020
pubmed: 28 2 2020
medline: 25 11 2020
Statut: epublish

Résumé

Neuroprotective treatments in ischemic stroke are focused to reduce the pernicious effect of excitotoxicity, oxidative stress and inflammation. However, those cellular and molecular mechanisms may also have beneficial effects, especially during the late stages of the ischemic stroke. The objective of this study was to investigate the relationship between the clinical improvement of ischemic stroke patients and the time-dependent excitotoxicity and inflammation. We included 4295 ischemic stroke patients in a retrospective study. The main outcomes were intra and extra-hospital improvement. High glutamate and IL-6 levels at 24 hours were associated with a worse intra-hospital improvement (OR:0.993, 95%CI: 0.990-0.996 and OR:0.990, 95%CI: 0.985-0.995). High glutamate and IL-6 levels at 24 hours were associated with better extra-hospital improvement (OR:1.13 95%CI, 1.07-1.12 and OR:1.14, 95%CI, 1.09-1.18). Effective reperfusion after recanalization showed the best clinical outcome. However, the long term recovery is less marked in patients with an effective reperfusion. The variations of glutamate and IL6 levels in the first 24 hours clearly showed a relationship between the molecular components of the ischemic cascade and the clinical outcome of patients. Our findings suggest that the rapid reperfusion after recanalization treatment blocks the molecular response to ischemia that is associated with restorative processes.

Identifiants

pubmed: 32103074
doi: 10.1038/s41598-020-60216-x
pii: 10.1038/s41598-020-60216-x
pmc: PMC7044227
doi:

Substances chimiques

Interleukin-6 0
Glutamic Acid 3KX376GY7L
Tissue Plasminogen Activator EC 3.4.21.68

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3513

Références

Bai, J. & Lyden, P. D. Revisiting cerebral postischemic reperfusion injury: new insights in understanding reperfusion failure, hemorrhage, and edema. International Journal of Stroke 10, 143–152 (2015).
doi: 10.1111/ijs.12434
Lakhan, S. E., Kirchgessner, A. & Hofer, M. Inflammatory mechanisms in ischemic stroke: therapeutic approaches. Journal of translational medicine 7, 97 (2009).
doi: 10.1186/1479-5876-7-97
Iadecola, C. & Anrather, J. The immunology of stroke: from mechanisms to translation. Nature medicine 17, 796 (2011).
doi: 10.1038/nm.2399
Khatri, R., McKinney, A. M., Swenson, B. & Janardhan, V. Blood–brain barrier, reperfusion injury, and hemorrhagic transformation in acute ischemic stroke. Neurology 79, S52–S57 (2012).
doi: 10.1212/WNL.0b013e3182697e70
Xing, C., Arai, K., Lo, E. H. & Hommel, M. Pathophysiologic cascades in ischemic stroke. International Journal of Stroke 7, 378–385 (2012).
doi: 10.1111/j.1747-4949.2012.00839.x
Savitz, S. I., Baron, J.-C., Yenari, M. A., Sanossian, N. & Fisher, M. Reconsidering neuroprotection in the reperfusion era. Stroke 48, 3413–3419 (2017).
doi: 10.1161/STROKEAHA.117.017283
Chamorro, Á. Neuroprotectants in the Era of Reperfusion Therapy. Journal of stroke 20, 197 (2018).
doi: 10.5853/jos.2017.02901
Chamorro, A., Dirnagl, U., Urra, X. & Planas, A. M. Neuroprotection in acute stroke: targeting excitotoxicity, oxidative and nitrosative stress, and infl ammation. Lancet Neurology 15, 869–881, https://doi.org/10.1016/s1474-4422(16)00114-9 (2016).
doi: 10.1016/s1474-4422(16)00114-9 pubmed: 27180033
Ikonomidou, C. & Turski, L. Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury? The Lancet Neurology 1, 383–386 (2002).
doi: 10.1016/S1474-4422(02)00164-3
Sughrue, M. E., Mehra, A., Connolly, E. S. Jr. & D’Ambrosio, A. L. Anti-adhesion molecule strategies as potential neuroprotective agents in cerebral ischemia: a critical review of the literature. Inflammation research: official journal of the European Histamine Research Society… [et al.] 53, 497–508, https://doi.org/10.1007/s00011-004-1282-0 (2004).
doi: 10.1007/s00011-004-1282-0
Moskowitz, M. A., Lo, E. H. & Iadecola, C. The science of stroke: mechanisms in search of treatments. Neuron 67, 181–198, https://doi.org/10.1016/j.neuron.2010.07.002 (2010).
doi: 10.1016/j.neuron.2010.07.002 pubmed: 20670828 pmcid: 2957363
Zhao, W. B. et al. Long-term outcomes of acute ischemic stroke patients treated with endovascular thrombectomy: A real-world experience. Journal of the Neurological Sciences 390, 77–83, https://doi.org/10.1016/j.jns.2018.03.004 (2018).
doi: 10.1016/j.jns.2018.03.004 pubmed: 29801912
Muruet, W., Rudd, A., Wolfe, C. D. & Douiri, A. Long-term survival after intravenous thrombolysis for ischemic stroke: a propensity score-matched cohort with up to 10-year follow-up. Stroke 49, 607–613 (2018).
doi: 10.1161/STROKEAHA.117.019889
Campbell, B. C. V. et al. Endovascular Thrombectomy for Ischemic Stroke Increases Disability-Free Survival, Quality of Life, and Life Expectancy and Reduces Cost. Frontiers in Neurology 8, https://doi.org/10.3389/fneur.2017.00657 (2017).
Budimkic, M. S. et al. Long-Term Prognosis in Ischemic Stroke Patients Treated with Intravenous Thrombolytic Therapy. Journal of Stroke & Cerebrovascular Diseases 26, 196–203, https://doi.org/10.1016/j.jstrokecerebrovasdis.2016.09.009 (2017).
doi: 10.1016/j.jstrokecerebrovasdis.2016.09.009
Enzmann, G., Kargaran, S. & Engelhardt, B. Ischemia–reperfusion injury in stroke: impact of the brain barriers and brain immune privilege on neutrophil function. Therapeutic Advances in Neurological Disorders 11, 1756286418794184 (2018).
Eltzschig, H. K. & Eckle, T. Ischemia and reperfusion-from mechanism to translation. Nature Medicine 17, 1391–1401, https://doi.org/10.1038/nm.2507 (2011).
doi: 10.1038/nm.2507 pubmed: 22064429
Kinouchi, H. et al. Attenuation of focal cerebral ischemic-injury in transgenic mice overexpressing CuZn superoxide-dismutase. Proceedings of the National Academy of Sciences of the United States of America 88, 11158–11162, https://doi.org/10.1073/pnas.88.24.11158 (1991).
doi: 10.1073/pnas.88.24.11158 pubmed: 1763030 pmcid: 53093
Copin, J. C. et al. Recombinant tissue plasminogen activator induces blood–brain barrier breakdown by a matrix metalloproteinase‐9‐independent pathway after transient focal cerebral ischemia in mouse. European Journal of Neuroscience 34, 1085–1092 (2011).
doi: 10.1111/j.1460-9568.2011.07843.x
Iglesias-Rey, R. et al. Worse Outcome in Stroke Patients Treated with rt-PA Without Early Reperfusion: Associated Factors. Translational Stroke Research 9, 347–355, https://doi.org/10.1007/s12975-017-0584-9 (2018).
doi: 10.1007/s12975-017-0584-9 pubmed: 29116527
Wu, J. et al. Neuroprotective effects of sulfiredoxin-1 during cerebral ischemia/reperfusion oxidative stress injury in rats. Brain research bulletin 132, 99–108 (2017).
doi: 10.1016/j.brainresbull.2017.05.012
Guldris, N. et al. Influence of of the separation procedure on the properties of magnetic nanoparticles: Gaining in vitro stability and T-1-T-2 magnetic resonance imaging performance. Journal of Colloid and Interface Science 472, 229–236, https://doi.org/10.1016/j.jcis.2016.03.040 (2016).
doi: 10.1016/j.jcis.2016.03.040 pubmed: 27038785
Chamorro, Á., Dirnagl, U., Urra, X. & Planas, A. M. Neuroprotection in acute stroke: targeting excitotoxicity, oxidative and nitrosative stress, and inflammation. The Lancet Neurology 15, 869–881 (2016).
doi: 10.1016/S1474-4422(16)00114-9
Soares, B. P. et al. Reperfusion Is a More Accurate Predictor of Follow-Up Infarct Volume Than Recanalization A Proof of Concept Using CT in Acute Ischemic Stroke Patients. Stroke 41, E34–E40, https://doi.org/10.1161/strokeaha.109.568766 (2010).
doi: 10.1161/strokeaha.109.568766 pubmed: 19910542
Ribo, M. et al. Temporal profile of recanalization after intravenous tissue plasminogen activator - Selecting patients for rescue reperfusion techniques. Stroke 37, 1000–1004, https://doi.org/10.1161/01.STR.0000206443.96112.d9 (2006).
doi: 10.1161/01.STR.0000206443.96112.d9 pubmed: 16514102
Castillo, J., Dávalos, A. & Noya, M. Progression of ischaemic stroke and excitotoxic aminoacids. The Lancet 349, 79–82 (1997).
doi: 10.1016/S0140-6736(96)04453-4
Castillo, J., Dávalos, A., Naveiro, J. & Noya, M. Neuroexcitatory amino acids and their relation to infarct size and neurological deficit in ischemic stroke. Stroke 27, 1060–1065 (1996).
doi: 10.1161/01.STR.27.6.1060
Vila, N., Castillo, J., Davalos, A. & Chamorro, A. Proinflammatory cytokines and early neurological worsening in ischemic stroke. Stroke 31, 2325–2329, https://doi.org/10.1161/01.str.31.10.2325 (2000).
doi: 10.1161/01.str.31.10.2325 pubmed: 11022058
Vila, N. et al. Levels of anti-inflammatory cytokines and neurological worsening in acute ischemic stroke. Stroke 34, 671–675, https://doi.org/10.1161/01.str.0000057976.53301.69 (2003).
doi: 10.1161/01.str.0000057976.53301.69 pubmed: 12624290
Bustamante, A. et al. Prognostic value of blood interleukin-6 in the prediction of functional outcome after stroke: a systematic review and meta-analysis. J Neuroimmunol 274, 215–224, https://doi.org/10.1016/j.jneuroim.2014.07.015 (2014).
doi: 10.1016/j.jneuroim.2014.07.015 pubmed: 25091431
Ramiro, L., Simats, A., García-Berrocoso, T. & Montaner, J. Inflammatory molecules might become both biomarkers and therapeutic targets for stroke management. Therapeutic Advances in Neurological Disorders 11, 1756286418789340, https://doi.org/10.1177/1756286418789340 (2018).
doi: 10.1177/1756286418789340
Grønhøj, M. H., Clausen, B. H., Fenger, C. D., Lambertsen, K. L. & Finsen, B. Beneficial potential of intravenously administered IL-6 in improving outcome after murine experimental stroke. Brain, behavior, and immunity 65, 296–311 (2017).
doi: 10.1016/j.bbi.2017.05.019
White, J., Hart, R. & Fry, J. An evaluation of the Waters Pico-Tag system for the amino-acid analysis of food materials. Journal of Analytical Methods in Chemistry 8, 170–177 (1986).
Sims, J. R. et al. ABC/2 for rapid clinical estimate of infarct, perfusion, and mismatch volumes. Neurology 72, 2104–2110, https://doi.org/10.1212/WNL.0b013e3181aa5329 (2009).
doi: 10.1212/WNL.0b013e3181aa5329 pubmed: 19528517 pmcid: 2697964
Kharitonova, T. et al. Association of early National Institutes of Health Stroke Scale improvement with vessel recanalization and functional outcome after intravenous thrombolysis in ischemic stroke. Stroke 42, 1638–1643 (2011).
doi: 10.1161/STROKEAHA.110.606194

Auteurs

Pablo Hervella (P)

Clinical Neurosciences Research Laboratory, Health Research Institute of Santiago de Compostela (IDIS), Hospital Clínico Universitario, Santiago de Compostela, Spain. pablo.hervella.lorenzo@sergas.es.

Emilio Rodríguez-Castro (E)

Stroke Unit, Department of Neurology, Hospital Clínico Universitario, Santiago de Compostela, Spain.

Manuel Rodríguez-Yáñez (M)

Stroke Unit, Department of Neurology, Hospital Clínico Universitario, Santiago de Compostela, Spain.

Susana Arias (S)

Stroke Unit, Department of Neurology, Hospital Clínico Universitario, Santiago de Compostela, Spain.

María Santamaría-Cadavid (M)

Stroke Unit, Department of Neurology, Hospital Clínico Universitario, Santiago de Compostela, Spain.

Iria López-Dequidt (I)

Stroke Unit, Department of Neurology, Hospital Clínico Universitario, Santiago de Compostela, Spain.

Ana Estany-Gestal (A)

Unit of Methodology of the Research, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain.

Elena Maqueda (E)

Clinical Neurosciences Research Laboratory, Health Research Institute of Santiago de Compostela (IDIS), Hospital Clínico Universitario, Santiago de Compostela, Spain.

Ignacio López-Loureiro (I)

Clinical Neurosciences Research Laboratory, Health Research Institute of Santiago de Compostela (IDIS), Hospital Clínico Universitario, Santiago de Compostela, Spain.

Tomás Sobrino (T)

Clinical Neurosciences Research Laboratory, Health Research Institute of Santiago de Compostela (IDIS), Hospital Clínico Universitario, Santiago de Compostela, Spain.

Francisco Campos (F)

Clinical Neurosciences Research Laboratory, Health Research Institute of Santiago de Compostela (IDIS), Hospital Clínico Universitario, Santiago de Compostela, Spain.

José Castillo (J)

Clinical Neurosciences Research Laboratory, Health Research Institute of Santiago de Compostela (IDIS), Hospital Clínico Universitario, Santiago de Compostela, Spain.

Ramón Iglesias-Rey (R)

Clinical Neurosciences Research Laboratory, Health Research Institute of Santiago de Compostela (IDIS), Hospital Clínico Universitario, Santiago de Compostela, Spain. ramon.iglesias.rey@sergas.es.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH